Prevalence of HPV After Introduction of the Vaccination Program in the United States

• Published in: Pediatrics (Evanston) Vol. 137; no. 3; p. e20151968
• Main Authors: Markowitz, Lauri E, Liu, Gui, Hariri, Susan, Steinau, Martin, Dunne, Eileen F, Unger, Elizabeth R
• Format: Journal Article
• Language: English
• Published: United States 01.03.2016
• Subjects: Adolescent; Adult; Alphapapillomavirus - genetics; DNA, Viral - analysis; Female; Humans; Immunization Programs; Nutrition Surveys; Papillomavirus Infections - epidemiology; Papillomavirus Infections - prevention & control; Papillomavirus Vaccines - administration & dosage; Prevalence; Sexual Behavior; United States - epidemiology; Vaccination; Vaginal Smears; Young Adult; United States
• ISSN: 1098-4275
• DOI: 10.1542/peds.2015-1968

Since mid-2006, human papillomavirus (HPV) vaccination has been recommended for females aged 11 to 12 years and through 26 years if not previously vaccinated. HPV DNA prevalence was analyzed in cervicovaginal specimens from females aged 14 to 34 years in NHANES in the prevaccine era (2003-2006) and 4 years of the vaccine era (2009-2012) according to age group. Prevalence of quadrivalent HPV vaccine (4vHPV) types (HPV-6, -11, -16, and -18) and other HPV type categories were compared between eras. Prevalence among sexually active females aged 14 to 24 years was also analyzed according to vaccination history. Between the prevacccine and vaccine eras, 4vHPV type prevalence declined from 11.5% to 4.3% (adjusted prevalence ratio [aPR]: 0.36 [95% confidence interval (CI): 0.21-0.61]) among females aged 14 to 19 years and from 18.5% to 12.1% (aPR: 0.66 [95% CI: 0.47-0.93]) among females aged 20 to 24 years. There was no decrease in 4vHPV type prevalence in older age groups. Within the vaccine era, among sexually active females aged 14 to 24 years, 4vHPV type prevalence was lower in vaccinated (≥1 dose) compared with unvaccinated females: 2.1% vs 16.9% (aPR: 0.11 [95% CI: 0.05-0.24]). There were no statistically significant changes in other HPV type categories that indicate cross-protection. Within 6 years of vaccine introduction, there was a 64% decrease in 4vHPV type prevalence among females aged 14 to 19 years and a 34% decrease among those aged 20 to 24 years. This finding extends previous observations of population impact in the United States and demonstrates the first national evidence of impact among females in their 20s.